Alphatec Holdings, Inc. (NASDAQ:ATEC) Expected to Earn FY2025 Earnings of $0.32 Per Share

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Rating) – Equities research analysts at HC Wainwright dropped their FY2025 earnings estimates for Alphatec in a research report issued on Wednesday, March 1st. HC Wainwright analyst S. Lee now forecasts that the medical technology company will post earnings of $0.32 per share for the year, down from their prior estimate of $0.35. HC Wainwright currently has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Alphatec’s current full-year earnings is ($1.05) per share. HC Wainwright also issued estimates for Alphatec’s FY2026 earnings at $0.74 EPS and FY2027 earnings at $1.37 EPS.

Several other research firms have also weighed in on ATEC. Lake Street Capital boosted their target price on shares of Alphatec from $16.50 to $20.00 and gave the company a “buy” rating in a research note on Thursday, January 12th. Needham & Company LLC reiterated a “buy” rating and set a $18.00 target price on shares of Alphatec in a research note on Wednesday. Finally, Morgan Stanley boosted their target price on shares of Alphatec from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Alphatec presently has an average rating of “Moderate Buy” and an average price target of $16.25.

Alphatec Stock Up 3.0 %

Shares of NASDAQ:ATEC opened at $15.54 on Thursday. The company has a current ratio of 2.14, a quick ratio of 1.33 and a debt-to-equity ratio of 29.74. The company has a fifty day simple moving average of $13.13 and a 200 day simple moving average of $10.64. The firm has a market cap of $1.63 billion, a PE ratio of -10.57 and a beta of 1.25. Alphatec has a 12-month low of $5.73 and a 12-month high of $16.15.

Insider Buying and Selling

In other Alphatec news, EVP Craig E. Hunsaker sold 80,023 shares of the company’s stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $16.00, for a total value of $1,280,368.00. Following the completion of the sale, the executive vice president now directly owns 1,346,828 shares of the company’s stock, valued at approximately $21,549,248. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Craig E. Hunsaker sold 80,023 shares of the stock in a transaction that occurred on Wednesday, March 1st. The shares were sold at an average price of $16.00, for a total transaction of $1,280,368.00. Following the completion of the sale, the executive vice president now directly owns 1,346,828 shares of the company’s stock, valued at $21,549,248. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Patrick Miles sold 60,000 shares of the company’s stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $13.05, for a total value of $783,000.00. Following the completion of the transaction, the chief executive officer now directly owns 5,601,633 shares in the company, valued at approximately $73,101,310.65. The disclosure for this sale can be found here. Insiders sold 564,821 shares of company stock valued at $7,781,975 over the last 90 days. 33.93% of the stock is currently owned by company insiders.

Institutional Trading of Alphatec

Several institutional investors and hedge funds have recently bought and sold shares of ATEC. HighTower Advisors LLC raised its holdings in Alphatec by 10.8% during the 1st quarter. HighTower Advisors LLC now owns 104,339 shares of the medical technology company’s stock worth $1,201,000 after buying an additional 10,212 shares during the period. MetLife Investment Management LLC raised its holdings in Alphatec by 55.0% during the 1st quarter. MetLife Investment Management LLC now owns 39,788 shares of the medical technology company’s stock worth $458,000 after buying an additional 14,125 shares during the period. Rhumbline Advisers raised its holdings in Alphatec by 3.7% during the 1st quarter. Rhumbline Advisers now owns 74,379 shares of the medical technology company’s stock worth $855,000 after buying an additional 2,671 shares during the period. BlackRock Inc. increased its holdings in shares of Alphatec by 0.7% in the 1st quarter. BlackRock Inc. now owns 4,943,013 shares of the medical technology company’s stock valued at $56,845,000 after purchasing an additional 34,257 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Alphatec by 2.3% in the 1st quarter. Vanguard Group Inc. now owns 3,431,921 shares of the medical technology company’s stock valued at $39,467,000 after purchasing an additional 77,959 shares during the period. Institutional investors and hedge funds own 48.59% of the company’s stock.

About Alphatec

(Get Rating)

Alphatec Holdings, Inc engages in the design, development, and marketing of spinal fusion technology products and solutions for the treatment of spinal disorders. It offers intra-operative information and neuromonitoring technologies, access systems, interbody implants, fixation systems, and various biologics offerings.